{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-171310","form_type":"8-K","ticker":null,"cik":"0001840574","company_name":"Verve Therapeutics, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.665692+00:00","generated_at":"2026-06-01T00:46:09.184084+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Verve Therapeutics appoints Jodie Morrison and Vertex exec Nia Tatsis to board","bullets":["Board expanded to nine members; Morrison (Class I, term to 2025) and Tatsis (Class III, term to 2027) elected June 26, 2024.","Morrison is independent; Tatsis is an executive officer of Vertex, Verve's collaborator under a 2022 strategic deal.","Each new director received an option for 267,541 shares at $5.02 per share, vesting over three years.","Tatsis's appointment deepens ties with Vertex, which paid Verve $25M upfront and up to $406M in milestones and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-171310","json":"https://secwatch.observer/filing/0001193125-24-171310.json","markdown":"https://secwatch.observer/filing/0001193125-24-171310.md","text":"https://secwatch.observer/filing/0001193125-24-171310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/d821295d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:46:09.184084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da5c10daa0","claim":"Jodie Morrison was elected as Director at Verve Therapeutics, Inc..","evidence_excerpt":"elected, effective immediately, Jodie Morrison as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fcbad06bd4","claim":"Ourania \"Nia\" Tatsis, Ph.D. was elected as Director at Verve Therapeutics, Inc..","evidence_excerpt":"Ourania \"Nia\" Tatsis, Ph.D. as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}